Klaus R. Dr Veitinger, Director at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 391 shares at $272.10 ($106K) on 2015-04-10, disclosed to the SEC on 2015-04-14.
Scheduled sale ($106k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TCDA | SELL | 2019-09-30 | $132K | — | Filing → |
| TCDA | SELL | 2019-08-28 | $139K | — | Filing → |
| TCDA | SELL | 2019-07-29 | $133K | — | Filing → |